Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid TumorsSuzanne Leijen, Robin M J M van Geel, Anna C Pavlick, et al.Lancet (London, England)|May 22, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialGerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.Cancer Immunology, Immunotherapy : CII|May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world dataJustin C Moser, Shailender Bhatia, Asim Amin, et al.JAMA|June 7, 2011
KIT as a therapeutic target in metastatic melanomaRichard D Carvajal, Cristina R Antonescu, Jedd D Wolchok, et al.European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.Pageof 11